fat_, it is possible that June 7 will pass w/o some kind of news, that Is the pattern we have seen. But, IMO, an A2-73 trail of bread crumbs leading to AAIC in Toronto is more likely. News lately has not come directly from AVXL. The trail of anecdotes has become obvious. I am looking for a more substantial comment from an interested party(FDA, MJF, other) that will make the July conference unbearably dramatic.
Is there a pattern developing here? A2-73 seems to present the promise of great things to come for people who have been w/o hope till now. Time will tell. BTW, prayer works, just ask a cancer survivor. We all know someone who will benefit.
If this progress means these kids and their families have an effective treatment them our investment $$ and time here have been well spent.
I get the whole time line/event/possibilities thing going on also. At any moment we could see either AD/Rhett/Parkinson/Dementia/Epilepsy/other news from anywhere, either AVXL or BP, or FDA or other 3rd party. I do think the June 7th session is a low speed fly-by. I do think July could be full AD fire power demo. I do think at any time a 3rd party/reg body or BP could pop some news of consequence. Between BP secret handshakes and AAIC black out rules through July we need some kind of PEEP's, a whisper, a wink-wink. I'm dying over here.
So this is simple , "show the flag" day??
I have owned MSTX for a very long time(yrs) and am delighted to see it move. Please summarize what is now going on w/trials and results. I have looked and do not see anything big, except this conference. Thanks in advance for your insights.
AAIC in Toronto July-24-28.Question is, how the hell do we live between now and then?
Hope you are right about the timing. We see so many different paths for news with AVXL, more news from FDA helps the overall credibility story. Someone observed that 3rd party analysis and partnership planning will take longer than simpler trials PR by AVXL. Sooner would be great but I am here for the long run.
This is a helpful train of thought. Attempting to define success for a broader (multiple indications) treatment path never studied or measured against specifics. Success with AD is the immediate goal, however the larger bull point we really do not get. What else do we expect to include in the definition of success for A 2-73. That is a challenging and classy problem to have.
It is reasonable to expect changes in vision, hearing, taste and other senses...over time. BR